title: Validation of contemporary guidelines for bone scintigraphy in prostate cancer staging: A prospective study in patients undergoing radical prostatectomy.
abstract: OBJECTIVE
  The aim of this study was to evaluate, using international urology and oncology guidelines, the criteria for performing bone scintigraphy (BS) in patients with newly diagnosed prostate cancer in a prospective setting with 2 years of follow-up after prostatectomy.
  
  
  METHODS
  In a prospective setting, criteria from European and US urology and oncology guidelines were evaluated in 220 unselected patients with BS performed as a routine investigation before radical prostatectomy. A prostate-specific antigen level of 0.1 ng/ml or lower after surgery was considered successful and was used as a measure of true-negative BS.
  
  
  RESULTS
  Overall, 200 out of 220 patients (91%) experienced successful radical prostatectomy at 6 months, with a 2 year success rate of 83%. The proportion of redundant BS ranged from 56% to 89% among the guidelines, whereas the outcome after radical prostatectomy was 93% within 6 months after surgery and 86-89% after 2 years of follow-up, without significant differences among guideline recommendations.
  
  
  CONCLUSIONS
  The guidelines from the American Urological Association and the criteria recently published by the present group proposed the largest proportion of redundant BS without compromising patient-related outcome.
authors: a 1 Department of Nuclear Medicine, Clinical Cancer Research Centre, Aalborg University Hospital , Aalborg, Denmark.|b 2 Department of Clinical Physiology, Viborg Hospital , Viborg, Denmark.|f 6 Department of Clinical Medicine, Aalborg University , Aalborg, Denmark.
authors: Helle D
authors: HD
authors: Zacho
authors: c 3 Department of Urology, Viborg Hospital , Viborg, Denmark.
authors: Tamás
authors: T
authors: Barsi
authors: d 4 Department of Nuclear Medicine, Regional Hospital West Jutland , Herning, Denmark.
authors: Jesper C
authors: JC
authors: Mortensen
authors: a 1 Department of Nuclear Medicine, Clinical Cancer Research Centre, Aalborg University Hospital , Aalborg, Denmark.|e 5 Department of Clinical Physiology and Nuclear Medicine, Randers Hospital , Randers, Denmark.
authors: Henrik
authors: H
authors: Bertelsen
authors: a 1 Department of Nuclear Medicine, Clinical Cancer Research Centre, Aalborg University Hospital , Aalborg, Denmark.|f 6 Department of Clinical Medicine, Aalborg University , Aalborg, Denmark.
authors: Lars J
authors: LJ
authors: Petersen
mesh_terms: D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D001842:Bone and Bones / Q000000981:diagnostic imaging*; D015331:Cohort Studies; D003718:Denmark; D006801:Humans; D007610:Kallikreins / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D013669:Technetium Tc 99m Medronate
chemical_list: D019275:Radiopharmaceuticals; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen; D013669:Technetium Tc 99m Medronate
keywords: Bone scan; follow-up after radical prostatectomy; guidelines; prostate cancer; staging